Keros Therapeutics, Inc. (NASDAQ: KROS) reported Q3 EPS of ($1.33), $0.02 better than the analyst estimate of ($1.35). Revenue for the quarter came in at $8 thousand.

For earnings history and earnings-related data on Keros Therapeutics, Inc. (KROS) click here.